Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial
Background and Purpose— The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial found that treatment with atorvastatin 80 mg per day reduced the risk of stroke and cardiovascular events in patients with a recent transient ischemic attack (TIA) or stroke. We hypothesized th...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
[December 2008]
|
| In: |
Stroke
Year: 2008, Jahrgang: 39, Heft: 12, Pages: 3297-3302 |
| ISSN: | 1524-4628 |
| DOI: | 10.1161/STROKEAHA.108.516450 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1161/STROKEAHA.108.516450 Verlag, lizenzpflichtig, Volltext: https://www.ahajournals.org/doi/10.1161/strokeaha.108.516450 
|
| Verfasserangaben: | Henrik Sillesen, MD, DMSc, Pierre Amarenco, MD, Michael G. Hennerici, MD, PhD, Alfred Callahan, MD, Larry B. Goldstein, MD, Justin Zivin, MD, PhD, Michael Messig, PhD, and K. Michael Welch, MD, ChB |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1752302494 | ||
| 003 | DE-627 | ||
| 005 | 20230427020428.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210324s2008 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/STROKEAHA.108.516450 |2 doi | |
| 035 | |a (DE-627)1752302494 | ||
| 035 | |a (DE-599)KXP1752302494 | ||
| 035 | |a (OCoLC)1341401141 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Sillesen, Henrik |d 1956- |e VerfasserIn |0 (DE-588)1229995005 |0 (DE-627)1752302729 |4 aut | |
| 245 | 1 | 0 | |a Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis |b a secondary analysis of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial |c Henrik Sillesen, MD, DMSc, Pierre Amarenco, MD, Michael G. Hennerici, MD, PhD, Alfred Callahan, MD, Larry B. Goldstein, MD, Justin Zivin, MD, PhD, Michael Messig, PhD, and K. Michael Welch, MD, ChB |
| 264 | 1 | |c [December 2008] | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 24.03.2021 | ||
| 520 | |a Background and Purpose— The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial found that treatment with atorvastatin 80 mg per day reduced the risk of stroke and cardiovascular events in patients with a recent transient ischemic attack (TIA) or stroke. We hypothesized this benefit would be greatest in the subgroup of patients with carotid stenosis.Methods— The SPARCL trial randomized patients with TIA or stroke within 1 to 6 months without known coronary heart disease (CHD) and low-density lipoprotein cholesterol 100 to 190 mg/dL to treatment with atorvastatin 80 mg per day or placebo. Investigators identified subjects as having carotid stenosis not requiring revascularization at the time of randomization. Of the total SPARCL population, 1007 were documented as having carotid stenosis at baseline, 3271 did not, and the status of 453 was unknown.Results— We found no heterogeneity in the treatment effect for the SPARCL primary (fatal and nonfatal stroke) and secondary end points between the group with and without carotid stenosis. The group with carotid artery stenosis had greater benefit when all cerebro- and cardiovascular events were combined. In the group with carotid artery stenosis, treatment with atorvastatin was associated with a 33% reduction in the risk of any stroke (hazard ratio [HR] 0.67, 95% confidence interval [CI] 0.47, 0.94; P=0.02), and a 43% reduction in risk of major coronary events (HR 0.57, 95% CI 0.32, 1.00; P=0.05). Later carotid revascularization was reduced by 56% (HR 0.44, 95% CI 0.24, 0.79; P=0.006) in the group randomized to atorvastatin.Conclusion— Consistent with the overall results of the SPARCL intention to treat population, intense lipid lowering with atorvastatin reduced the risk of cerebro- and cardiovascular events in patients with and without carotid stenosis. The carotid stenosis group may have greater benefit. | ||
| 700 | 1 | |a Amarenco, Pierre |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hennerici, Michael G. |d 1948- |e VerfasserIn |0 (DE-588)11587545X |0 (DE-627)077527704 |0 (DE-576)290126444 |4 aut | |
| 700 | 1 | |a Callahan, Alfred |e VerfasserIn |4 aut | |
| 700 | 1 | |a Goldstein, Larry B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zivin, Justin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Messig, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Welch, K. Michael |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Stroke |d New York, NY : Association, 1970 |g 39(2008), 12 vom: Dez., Seite 3297-3302 |h Online-Ressource |w (DE-627)266879985 |w (DE-600)1467823-8 |w (DE-576)075145731 |x 1524-4628 |7 nnas |a Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis a secondary analysis of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial |
| 773 | 1 | 8 | |g volume:39 |g year:2008 |g number:12 |g month:12 |g pages:3297-3302 |g extent:6 |a Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis a secondary analysis of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial |
| 856 | 4 | 0 | |u https://doi.org/10.1161/STROKEAHA.108.516450 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.ahajournals.org/doi/10.1161/strokeaha.108.516450 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210324 | ||
| 993 | |a Article | ||
| 994 | |a 2008 | ||
| 998 | |g 11587545X |a Hennerici, Michael G. |m 11587545X:Hennerici, Michael G. |d 60000 |d 62700 |e 60000PH11587545X |e 62700PH11587545X |k 0/60000/ |k 1/60000/62700/ |p 3 | ||
| 999 | |a KXP-PPN1752302494 |e 3893549404 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedDisp":"[December 2008]","dateIssuedKey":"2008"}],"id":{"doi":["10.1161/STROKEAHA.108.516450"],"eki":["1752302494"]},"name":{"displayForm":["Henrik Sillesen, MD, DMSc, Pierre Amarenco, MD, Michael G. Hennerici, MD, PhD, Alfred Callahan, MD, Larry B. Goldstein, MD, Justin Zivin, MD, PhD, Michael Messig, PhD, and K. Michael Welch, MD, ChB"]},"physDesc":[{"extent":"6 S."}],"relHost":[{"origin":[{"publisher":"Association ; Lippincott Williams & Wilkins","dateIssuedKey":"1970","dateIssuedDisp":"1970-","publisherPlace":"New York, NY ; Philadelphia, Pa."}],"id":{"issn":["1524-4628"],"eki":["266879985"],"zdb":["1467823-8"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"subtitle":"journal of the American Heart Association","title":"Stroke","title_sort":"Stroke"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 29.06.04"],"disp":"Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis a secondary analysis of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trialStroke","recId":"266879985","language":["eng"],"corporate":[{"roleDisplay":"Herausgebendes Organ","display":"American Heart Association","role":"isb"}],"pubHistory":["1.1970 -"],"part":{"volume":"39","text":"39(2008), 12 vom: Dez., Seite 3297-3302","extent":"6","year":"2008","pages":"3297-3302","issue":"12"}}],"title":[{"title":"Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis","subtitle":"a secondary analysis of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial","title_sort":"Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis"}],"person":[{"given":"Henrik","family":"Sillesen","role":"aut","display":"Sillesen, Henrik","roleDisplay":"VerfasserIn"},{"family":"Amarenco","given":"Pierre","display":"Amarenco, Pierre","roleDisplay":"VerfasserIn","role":"aut"},{"family":"Hennerici","given":"Michael G.","roleDisplay":"VerfasserIn","display":"Hennerici, Michael G.","role":"aut"},{"family":"Callahan","given":"Alfred","display":"Callahan, Alfred","roleDisplay":"VerfasserIn","role":"aut"},{"family":"Goldstein","given":"Larry B.","display":"Goldstein, Larry B.","roleDisplay":"VerfasserIn","role":"aut"},{"given":"Justin","family":"Zivin","role":"aut","roleDisplay":"VerfasserIn","display":"Zivin, Justin"},{"family":"Messig","given":"Michael","roleDisplay":"VerfasserIn","display":"Messig, Michael","role":"aut"},{"family":"Welch","given":"K. Michael","display":"Welch, K. Michael","roleDisplay":"VerfasserIn","role":"aut"}],"note":["Gesehen am 24.03.2021"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1752302494","language":["eng"]} | ||
| SRT | |a SILLESENHEATORVASTAT2008 | ||